Table 2.
Baseline characteristics of the patients with mannose binding lectin (MBL) deficiency and patients without MBL deficiency in the microbiome subcohort study. GOLD class was calculated based on the 2011 guidelines. p Values were calculated through pairwise comparisons by T test for parametrical data and Mann-Whitney U test for non-parametrical data
| MBL deficient genotypes | MBL non-deficient genotypes | p Value | |
| Demographics and major comorbidities | |||
| N | 34 | 107 | |
| Age, years (SD) | 72.8 (±7.3) | 70.8 ± (8.2) | 0.2 |
| Age at diagnosis, years (SD) | 59.5 (±9.1) | 60.2 (±11.9) | 0.8 |
| Male gender (%) | 22 (64.7) | 67 (62.6) | 0.8 |
| Active smokers (%) | 7 (20.6) | 21 (19.6) | 0.9 |
| Cigarette smoking by pack years (SD) | 45.1 (±29.9) | 41.7 (±28.9) | 0.6 |
| Body mass index (SD) | 28.2 (±5.3) | 28.1 (±5.6) | 0.9 |
| Myocardial Infarction (%) | 4 (12.1) | 12 (11.2) | 0.9 |
| CABG (%) | 3 (8.8) | 12 (11.2) | 0.7 |
| Angina (%) | 6 (18.2) | 24 (22.4) | 0.6 |
| Stroke (%) | 7 (20.6) | 6 (5.6) | 0.008 |
| Diabetes (%) | 5 (14.7) | 22 (20.6) | 0.4 |
| COPD characteristics | |||
| FEV1 per cent predicted (SD) | 65.0 (±19.4) | 72.1 (±20.7) | 0.08 |
| MRC Dyspnoea Score (SD) | 3.0 (±1.5) | 2.58 (±1.4) | 0.1 |
| Exacerbations per year (SD) | 1.5 (±1.5) | 1.9 (±1.9) | 0.3 |
| Blood eosinophils >2% (%) | 16 (47.1) | 70 (65.4) | 0.06 |
| GOLD Score | 0.6* | ||
| A (%) | 2 (5.9) | 15 (14.0) | – |
| B (%) | 14 (41.2) | 38 (35.5) | – |
| C (%) | 2 (5.9) | 4 (3.7) | – |
| D (%) | 16 (47.1) | 50 (46.7) | – |
| SGRQ (SD) | 47.8 (±23.3) | 39.7 (±22.6) | 0.07 |
| On LTOT (%) | 0 (0) | 5 (4.7) | 0.2 |
| Medications | |||
| ICS/LABA (%) | 22 (64.7) | 62 (57.9) | 0.5 |
| LABA alone (%) | 3 (8.8) | 13 (12.1) | 0.6 |
| LAMA (%) | 19 (55.9) | 51 (47.7) | 0.4 |
| Mucolytic (%) | 7 (20.6) | 10 (9.3) | 0.08 |
| Aspirin (%) | 10 (29.4) | 27 (25.2) | 0.6 |
| β blocker (%) | 5 (14.7) | 13 (12.1) | 0.7 |
| Statin (%) | 20 (58.8) | 56 (52.3) | 0.5 |
| ACE inhibitor (%) | 7 (20.6) | 30 (28.0) | 0.4 |
| Clopidogrel (%) | 3 (8.8) | 7 (6.5) | 0.7 |
*indicates Χ2 test across all four GOLD groups.
CABG, coronary artery bypass graft; GOLD, Global Obstructive Lung Disease; ICS, inhaled corticosteroids; LABA, long-acting β agonist; LAMA, long-acting muscarinic antagonist; LTOT, long-term oxygen therapy; SGRQ, St George’s Respiratory Questionnaire.